Jäger W, Meier C, Wildt L, Sauerbrei W, Lang N
University of Erlangen, Federal Republic of Germany.
Fertil Steril. 1988 Aug;50(2):223-7. doi: 10.1016/s0015-0282(16)60063-8.
CA-125 is an antigenic determinant expressed on ovarian cancer cells and serves as serum marker in patients with ovarian cancer. It has also been detected, however, in serum of healthy women and in patients with benign gynecologic diseases. Previous studies in patients with ovarian hyperstimulation syndrome suggested that the production of CA-125 is correlated with proliferative ovarian activity. In this study, we describe the pattern of CA-125 secretion in 13 healthy women during menstrual cycle and during hormonal contraceptive treatment. That pattern is characterized by an increase of CA-125 serum concentrations parallel to the growth of the dominant follicle. It was not observed during hormonal contraceptive treatment. We conclude that CA-125 serum levels during menstrual cycle seem to be dependent upon the cyclic changes in the female genital tract.
CA - 125是一种在卵巢癌细胞上表达的抗原决定簇，可作为卵巢癌患者的血清标志物。然而，在健康女性血清以及患有良性妇科疾病的患者中也检测到了CA - 125。先前对卵巢过度刺激综合征患者的研究表明，CA - 125的产生与卵巢的增殖活性相关。在本研究中，我们描述了13名健康女性在月经周期和激素避孕治疗期间CA - 125的分泌模式。该模式的特征是CA - 125血清浓度的增加与优势卵泡的生长平行。在激素避孕治疗期间未观察到这种情况。我们得出结论，月经周期中CA - 125的血清水平似乎取决于女性生殖道的周期性变化。
